Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes

Haller, Hermann, Ito, Sadayoshi, Izzo, Joseph L., Januszewicz, Andrzej, Katayama, Shigehiro, Menne, Jan, Mimran, Albert, Rabelink, Ton J. +4 more·2011·New England Journal of Medicine
DOI 10.1056/nejmoa1007994

Cited by (793)

Items 301–400 of 793

  1. Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk
    Sébastien Foulquier, Michael Böhm, Roland Erich Schmieder, Peter Sleight, Koon Kang Teo, Salim Yusuf, Helmut Schumacher, Thomas Unger · 2014 · Journal of Hypertension
  2. Cardiorenal Syndrome in Hypertensive Rats: Microalbuminuria, Inflammation and Ventricular Hypertrophy
    M. MOUBARAK, Khalil Jabbour, Viviane Smayra, Éliane Chouery, Youakim Saliba, Victor A. Jebara, Nassim Farès · 2012 · Physiological Research
  3. RAS inhibitors’ dose-dependent efficacy: myth or reality?
    Stefano Taddei · 2015 · Current Medical Research and Opinion
  4. Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model
    Hui Shao, Shuang Yang, Charles Stoecker, Vivian Andrew Fonseca, Dongzhe Hong, Lizheng Shi · 2019 · Value in Health
  5. Aberrant Activation of the Intrarenal Renin-Angiotensin System in the Developing Kidneys of Type 2 Diabetic Rats
    Yu-Yan Fan, Hiroyuki Kobori, Daisuke Nakano, Hirofumi Hitomi, Hirohito Mori, Tsutomu Masaki, Y.-X. Sun, Niu Zhi, Luo Zhang, Wen Huang et al. · 2013 · Hormone and Metabolic Research
  6. Specific Blood Pressure Targets for Patients With Diabetic Nephropathy?
    Guido M. Grassi, Giuseppe Mancia, Peter M. Nilsson · 2016 · Diabetes Care
  7. Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study
    Seng Chan You, Hojun Park, Dukyong Yoon, Soo-Young Park, Boyoung Joung, Rae Woong Park · 2017 · The Korean Journal of Internal Medicine
  8. Association of blood pressure with cardiovascular outcome and mortality: results from the KNOW-CKD study
    Jee Young Lee, Jung Tak Park, Young Su Joo, Changhyun Lee, Hae‐Ryong Yun, Tae Ik Chang, Yeong-Hoon Kim, Wookyung Chung, Tae‐Hyun Yoo, Shin‐Wook Kang et al. · 2021 · Nephrology Dialysis Transplantation
  9. Overview of the renin-angiotensin system in diabetic nephropathy
    Farzaneh Karimi, Maryam Maleki, Ahmad Movahedpour, Mehdi Alizadeh, Ebrahim Kharazinejad, Mohammad Sabaghan · 2024 · Journal of the Renin-Angiotensin-Aldosterone System
  10. Chronic Kidney Disease Stages 1–3
    Fink Ha, Areef Ishani, Benjamin C. Taylor, Greer Nl, Roderick H. MacDonald, Dominic Rossini, Sameea Sadiq, Srilakshmi Lankireddy, Robert L Kane, Wilt Tj · 2012 · Europe PMC (PubMed Central)
  11. Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD)
    Ivan Formentini, María Bobadilla, Carolina Haefliger, Guido R. Hartmann, Mahmoud Loghman‐Adham, Jacques L. Mizrahi, Silvia Ines Pomposiello, Marco Prunotto, Matthias Meier · 2012 · Nephrology Dialysis Transplantation
  12. Hypertensive subjects with type-2 diabetes, the sympathetic nervous system, and treatment implications
    Andrew J.S. Coats, John Malcolm Cruickshank · 2014 · International Journal of Cardiology
  13. Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy
    Chia-Jen Shih, Hung‐Ta Chen, Shu‐Chen Kuo, Szu‐Yuan Li, Pi-Hsiang Lai, Shuchen Chen, Shuo‐Ming Ou, Yung‐Tai Chen · 2016 · Canadian Medical Association Journal
  14. Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP 2C9, CYP 2J2 and Human Liver Microsomes
    Asuna Senda, Yuji Mukai, Tõru Hayakawa, Yuka Kato, Erik Eliasson, Anders Rane, Takaki Toda, Nobuo Inotsume · 2017 · Basic & Clinical Pharmacology & Toxicology
  15. Benefits and harms of lower blood pressure treatment targets: systematic review and meta-analysis of randomised placebo-controlled trials
    Mattias Brunström, Bo Carlberg · 2019 · BMJ Open
  16. The Legacy Effect in the Prevention of Cardiovascular Disease
    Esther Viñas Esmel, José Naval-Álvarez, Emilio Sacanella · 2020 · Nutrients
  17. Novedades en hipertensión arterial y diabetes mellitus
    Alberto Cordero, Iñaki Lekuona, Enrique Galve, Pilar Mazón · 2012 · Revista Española de Cardiología
  18. Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI
    Cong Ma, Cao Jian, Xue-Chun Lu, Guo Xin-Hong, Gao Yan, Liu Xian-Feng, Fan Li · 2012 · 老年心脏病学杂志：英文版
  19. Inhibition of the renin–angiotensin–aldosterone system
    Massimo Volpe, A.H. Jan Danser, Joël Ménard, Bernard Waeber, Dominik N. Mueller, Aldo Pietro Maggioni, Luis Miguel Ruilope · 2012 · Journal of Hypertension
  20. Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis
    Danka J. F. Stuijver, Erica Romualdi, Bregje van Zaane, Leon Bax, Harry Roger Buller, Victor E. A. Gerdes, Alessandro Squizzato · 2014 · Internal and Emergency Medicine
  21. Redefining Blood Pressure Targets in High-Risk Patients?: Lessons From Coronary Endpoints in Recent Randomized Clinical Trials
    Massimo Volpe, Giuliano Tocci · 2011 · American Journal of Hypertension
  22. Not just numbers, but years of science: Putting the ACE inhibitor—ARB meta-analyses into context
    Roberto Ferrari, Giuseppe M.C. Rosano · 2013 · International Journal of Cardiology
  23. Interventions in type 2 diabetes mellitus and cardiovascular mortality–An overview of clinical trials
    Benjamin Burggraaf, Manuel Castro Cabezas · 2017 · European Journal of Internal Medicine
  24. Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database
    Akira Fukui, Hidehiro Kaneko, Akira Okada, Yuichiro Yano, Hidetaka Itoh, Satoshi Matsuoka, Kojiro Morita, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu et al. · 2021 · Nephrology Dialysis Transplantation
  25. High normal albuminuria is associated with arterial stiffness and carotid atherosclerosis in Korean patients with type 2 diabetes
    Hye Eun Yoon, E.S. Kim, Eun Yeong Mo, Seok Joon Shin, Sung Dae Moon, Je Ho Han · 2015 · Nutrition Metabolism and Cardiovascular Diseases
  26. Novel insight into the dangerous connection between diabetes and heart failure
    Carlo Lombardi, Valentina Spigoni, Elio Gorga, Alessandra Dei · 2016 · Herz
  27. Estrogen-Independent Activation of Estrogen Receptors
    Matthias Barton, Matthias R. Meyer, Eric R. Prossnitz · 2011 · Hypertension
  28. Effect of glycemic control on microalbuminuria development among type 2 diabetes with high-normal albuminuria
    Wei-Zhi Chen, Cheng‐Chieh Hung, Yu‐Wen Wen, Hsiao‐Chen Ning, Bing-Ru Gau, Yu‐Yao Huang · 2013 · Renal Failure
  29. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria
    Tsukasa Nakamura, Eiichi Sato, Mayuko Amaha, Yasuhiro Kawagoe, Sayaka Maeda, Sho‐ichi Yamagishi · 2011 · Journal of the Renin-Angiotensin-Aldosterone System
  30. Understanding and treating hypertension in diabetic populations.
    Massimo Volpe, Allegra Battistoni, Carmine Savoia, Giuliano Tocci · 2015 · PubMed Central
  31. Rationale and design of the Investigator-Steered Project on intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial
    Yu Jin, Lotte Jacobs, Marie Baelen, Lutgarde Thijs, Jean P. Renkin, Frank Hammer, Joëlle Kefer, Thibault Petit, Peter B. Verhamme, Stefan P. Janssens et al. · 2014 · Blood Pressure
  32. Microalbuminuria predicts the recurrence of cardiovascular events in patients with essential hypertension
    Alfonso Meccariello, Francesco Buono, Elvira Verrengia, Giuseppe Orefice, Fabrizia Grieco, Fabio Romeo, Bruno Trimarco, Carmine Morisco · 2016 · Journal of Hypertension
  33. Established and Emerging Strategies in the Treatment of Chronic Kidney Disease
    Julio E. Pena-Polanco, Linda F. Fried · 2016 · Seminars in Nephrology
  34. Individualization of Antihypertensive Drug Treatment
    Giuseppe Mancia, Guido M. Grassi · 2013 · Diabetes Care
  35. Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus—Clinical Practice Position Statement of the Polish Society of Nephrology
    Marcin Adamczak, Ilona Kurnatowska, Beata Naumnik, Tomasz P. Stompór, Leszek Tylicki, Magdalena Krajewska · 2024 · International Journal of Molecular Sciences
  36. Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Missed Dose in Type 2 Diabetes
    Josep Redón, Gernot Pichler · 2016 · American Journal of Hypertension
  37. Actual impact of angiotensin II receptor blocker or calcium channel blocker monotherapy on renal function in real-world patients
    Michihiro Satoh, Takuo Hirose, Hironori Satoh, Shingo Nakayama, Taku Obara, Takahisa Murakami, Tomoko Muroya, Kei Asayama, Masahiro Kikuya, Takefumi Mori et al. · 2022 · Journal of Hypertension
  38. Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review
    Rabeeyah Ahmed, Russell J. de Souza, Vincent Li, Laura E. Banfield, Sonia Savitri Anand · 2024 · Diabetologia
  39. Risk of acute myocardial infarction, stroke, or death in patients initiating olmesartan or other angiotensin receptor blockers — a cohort study using the Clinical Practice Research Datalink
    Esther H. Zhou, Kate Gelperin, Mark S Levenson, Martin Rose, Ya‐Hui Hsueh, David J. Graham · 2013 · Pharmacoepidemiology and Drug Safety
  40. Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria
    Marta Martin‐Lorenzo, Laura Gonzalez‐Calero, Paula J. Martínez, Montserrat Baldan Martin, Juan Antonio López, Gema Ruiz‐Hurtado, Fernando de la Cuesta, J. Segura, Jesús Vázquez, Fernando Vivanco et al. · 2017 · Scientific Reports
  41. The rationale and design of reduction of uncontrolled hypertension by Remote Monitoring and Telemedicine (REMOTE) study
    Midori Yatabe, Junichi Yatabe, Kei Asayama, Jan Albert Staessen, Blerim Mujaj, Lutgarde Thijs, Kyotaro Ito, Tomohiro Sonoo, Satoshi Morimoto, Atsuhiro Ichihara · 2017 · Blood Pressure
  42. Comparative risk of new‐onset hyperkalemia for antihypertensive drugs in patients with diabetic nephropathy: A Bayesian network meta‐analysis
    Zhu Simin, Juan Li, Xinyuan Zhao · 2020 · International Journal of Clinical Practice
  43. Olmesartan-associated enteropathy: new insights on the natural history? Report of two cases
    Annalisa Schiepatti, Federico Biagi, Davide Cumetti, Ombretta Luinetti, Aurelio Sonzogni, Amedeo Mugellini, Gino Roberto Corazza · 2015 · Scandinavian Journal of Gastroenterology
  44. The Nephroprotective Properties of Recombinant Human Erythropoietin in Kidney Transplantation: Experimental Facts and Clinical Proofs
    Nicolas Pallet, Marion Rabant, Ch. Legendre, Frank Martinez, Gabriel J. Choukroun · 2012 · American Journal of Transplantation
  45. Add-On Aliskiren Elicits Stronger Renoprotection Than High-Dose Valsartan in Type 2 Diabetic KKAy Mice That Do Not Respond to Low-Dose Valsartan
    Lei Bai, Daisuke Nakano, Yu-Yan Fan, Kento Kitada, Hirofumi Hitomi, Hiroyuki Kobori, Hirohito Mori, Tsutomu Masaki, Akira Nishiyama · 2012 · Journal of Pharmacological Sciences
  46. Effects of olmesartan on arterial stiffness in rats with chronic renal failure
    Yao Chen Chuang, Ming‐Shiou Wu, Yi-Kai Su, Kwang-Ming Fang · 2012 · Cardiovascular Diabetology
  47. Aliskiren Effect on Plaque Progression in Established Atherosclerosis Using High Resolution 3D MRI (ALPINE): A Double‐Blind Placebo‐Controlled Trial
    Georgeta Mihai, Juliet Varghese, Thomas Kampfrath, Liubov V. Gushchina, Lisa Hafer, Jeffrey A. Deiuliis, Andrei Maiseyeu, Orlando Paul Simonetti, Bo Lü, Sanjay Rajagopalan · 2013 · Journal of the American Heart Association
  48. Diabetische Nierenerkrankung (Update 2026)
    Harald Sourij, Felix Aberer, Marlies Antlanger, Johanna Brix, Daniel Cejka, Martin Clodi, Roland Edlinger, Kathrin Eller, Sabine Horn, Susanne Kaser et al. · 2016 · Wiener klinische Wochenschrift
  49. Blood pressure targets for hypertension in patients with type 2 diabetes
    Wilbert S. Aronow, Tatyana Shamliyan · 2018 · Annals of Translational Medicine
  50. Effects of renin–angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials
    Xing-hua LIU, Li Ma, Zhenjiang Li · 2020 · Journal of Endocrinological Investigation
  51. Bloqueantes del receptor mineralcorticoide en la enfermedad renal crónica
    Sara Erraez, Manuel López-Mesa, Pablo Gómez-Fernández · 2020 · Nefrología
  52. Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model
    Yuki Narita, Miki U. Ueda, Kohei Uchimura, Yutaka Kakizoe, Yoshikazu Miyasato, Teruhiko Mizumoto, Jun Morinaga, Manabu Hayata, Terumasa Nakagawa, Masataka Adachi et al. · 2016 · Journal of Pharmacological Sciences
  53. Urinary biomarkers to predict CKD: is the future in multi-marker panels?
    Claudia Pontillo, Harald Mischak · 2016 · Nephrology Dialysis Transplantation
  54. The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus
    Martin H. Strauss, Alistair S. Hall · 2017 · Canadian Journal of Diabetes
  55. Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol
    Lutgarde Thijs, Kei Asayama, Gladys Elena Maestre, Tine W. Hansen, Luk Buyse, Dongmei Wei, Jesús D. Melgarejo, Jana Brguljan-Hitij, Hao‐Min Cheng, Fábio de Souza et al. · 2021 · Blood Pressure
  56. ALTITUDE Trial and Dual RAS Blockade: The Alluring but Soft Science of the Surrogate End Point
    Franz H. Messerli, Sripal Bangalore · 2013 · The American Journal of Medicine
  57. Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers
    David J. Graham, Esther H. Zhou, Stephen J. McKean, Mark S Levenson, Katlyn Calia, Kate Gelperin, Xiao Xia Ding, Thomas E. MaCurdy, Chris M. Worrall, Jeffrey A. Kelman · 2013 · Pharmacoepidemiology and Drug Safety
  58. Olmesartan-based therapies
    Alejandro de la Sierra, Massimo Volpe · 2013 · Journal of Hypertension
  59. Sequential RAAS Blockade: Is It Worth the Risk?
    Frederik Persson, Peter R Rossing · 2014 · Advances in Chronic Kidney Disease
  60. Cardiac mortality in users of olmesartan, other angiotensin‐receptor blockers and angiotensin‐converting enzyme inhibitors
    Alexander Muir Walker, Caihua Liang, C. Robin Clifford, Crawford Parker, Allen Feldman · 2013 · Pharmacoepidemiology and Drug Safety
  61. Urinary Proteomics for Diagnosis and Monitoring of Diabetic Nephropathy
    Gemma E. Currie, Christian Delles · 2016 · Current Diabetes Reports
  62. Relationships between blood pressure lowering therapy and cardiovascular events in hypertensive patients with coronary artery disease and type 2 diabetes mellitus: The HIJ-CREATE sub-study
    Kazuho Kamishima, Hiroshi Ogawa, Kentaro Jujo, Junichi Yamaguchi, N Hagiwara · 2019 · Diabetes Research and Clinical Practice
  63. The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD
    João Roberto de Sá, Érika Bevilaqua Rangel, Luís Henrique Santos Canani, Andréa Carla Bauer, Gustavo Monteiro Escott, Themis Zelmanovitz, Marcello Casaccia Bertoluci, Sandra Pinho Silveiro · 2022 · Diabetology & Metabolic Syndrome
  64. Optimal achieved blood pressure for patients with stable coronary artery disease
    Chin‐Chou Huang, Hsin‐Bang Leu, Wei‐Hsian Yin, Wei-Kung Tseng, Yen‐Wen Wu, Tsung‐Hsien Lin, Hung‐I Yeh, Kuan‐Cheng Chang, Ji‐Hung Wang, Chin‐Chung Wu et al. · 2017 · Scientific Reports
  65. Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials
    Giuseppe Mancia, Helmut Schumacher, Michael Böhm, Johannes F.E. Mann, Josep Redón, Rita Facchetti, Roland Erich Schmieder, Eva Lonn, Koon Kang Teo, Salim Yusuf · 2020 · Journal of Hypertension
  66. Sulodexide for Diabetic Nephropathy: Another One Bites the Dust
    Andrew A. House, Matthew A. Weir · 2011 · American Journal of Kidney Diseases
  67. Comparison of Transaortic and Subclavian Approaches for Transcatheter Aortic Valve Replacement in Patients with No Transfemoral Access Options
    Asaad Akbar Khan, Jason Ciril Kovacic, Krysthel Engstrom, Allan S. Stewart, Anelechi Anyanwu, Sandeep Basnet, Melissa B. Aquino, Usman Baber, Luis Garcia, Umesh K Gidwani et al. · 2018 · Structural Heart
  68. Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy
    Xin Zhang, Huan Chen, Yanqi Lei, Xiaonan Zhang, Long Xu, Wenchao Liu, Zhenya Fan, Zequn Ma, Zhechang Yin, Lingyun Li et al. · 2021 · European Journal of Medicinal Chemistry
  69. Preventing microalbuminuria with benazepril, valsartan, and benazepril–valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study
    Piero Luigi Ruggenenti, Monica Cortinovis, Aneliya Ilieva Parvanova, Matias Trillini, Ilian Petrov Iliev, Antonio Carlo Bossi, Antonio Belviso, M Aparicio, Roberto Trevisan, Stefano Rota et al. · 2021 · PLoS Medicine
  70. A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients
    José Antonio García‐Donaire, J. Segura, César Cerezo, Luis Miguel Ruilope · 2011 · Blood Pressure
  71. Emerging drugs for chronic kidney disease
    Sergio Stefoni, Giuseppe Cianciolo, Olga Baraldi, Mario Iorio, Maria Laura Angelini · 2014 · Expert Opinion on Emerging Drugs
  72. Preemptive Olmesartan for the Delay or Prevention of Microalbuminuria in Diabetes
    Julie R. Ingelfinger · 2011 · New England Journal of Medicine
  73. Olmesartan vs. Ramipril in Elderly Hypertensive Patients: Review of Data from Two Published Randomized, Double-Blind Studies
    Stefano Omboni, Ettore Malacco, Jean-Michel Mallion, Paolo Fabrizzi, Massimo Volpe · 2014 · High Blood Pressure & Cardiovascular Prevention
  74. Antihypertensive Treatment and Renal Protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system
    Francesca Chiara Viazzi, Giovanna Leoncini, Roberto Pontremoli · 2013 · High Blood Pressure & Cardiovascular Prevention
  75. The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment?
    Flávio Danni Fuchs · 2012 · BMJ Evidence-Based Medicine
  76. Evolution of Treatment for Diabetic Nephropathy: Historical Progression from RAAS Inhibition and Onward
    Samuel S. Blumenthal · 2011 · Postgraduate Medicine
  77. Pharmacological Management of Diabetic Nephropathy
    Vasilios Papademetriou, Sofia Alataki, Konstantinos Stavropoulos, Christodoulos E. Papadopoulos, Kostas Bakogiannis, Kostas Tsioufis · 2019 · Current Vascular Pharmacology
  78. New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
    Massimo Volpe, Carmine Savoia · 2012 · Integrated Blood Pressure Control
  79. Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan.
    Guolong Yu, Xiaoqiu Liang, Xiu-Mei Xie, Tianlun Yang, Ming Sun, Shui‐Ping Zhao · 2002 · PubMed
  80. Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COhoRtE (DIACORE) study
    Myriam Rheinberger, Bettina Jung, Thomas Segiet, J. Nusser, Günther Kreisel, Axel Andreae, Jochen Manz, Gerhard Haas, Bernhard Banas, Klaus J. Stark et al. · 2019 · PLoS ONE
  81. A Strategic Investigation on Diabetic Nephropathy; Its Conceptual Model and clinical Manifestations: A Review
    Pranay Wal, Sachin Tyagi, Rashmi Saxena Pal, Anil Yadav, Riya Jaiswal · 2022 · Current Diabetes Reviews
  82. Blood Pressure Control in Patients with Diabetic Kidney Disease
    Yaeni Kim, Won Bae Kim, Jwa-Kyung Kim, Ju-Young Moon, Samel Park, Cheol Whee Park, Hoon Suk Park, Sang Heon Song, Tae‐Hyun Yoo, So-Young Lee et al. · 2022 · Electrolytes & Blood Pressure
  83. Antihypertensive Therapy and the J-curve: Fact or Fiction?
    Monique S. Tanna, Sripal Bangalore · 2015 · Current Hypertension Reports
  84. Preventing the development and progression of diabetic kidney disease: Where do we stand?
    Georgios Zagkotsis, Maria I. Markou, Eleni Paschou, Panagiota Papanikolaou, Nikos Sabanis · 2018 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  85. High glucose level and angiotensin II type 1 receptor stimulation synergistically amplify oxidative stress in renal mesangial cells
    Tetsuya Akaishi, Michiaki Abe, Hiroshi Okuda, Kota Ishizawa, Takaaki Abe, Tadashi Ishii, Sadayoshi Ito · 2019 · Scientific Reports
  86. Benefits and risks of antihypertensive medication in adults with different systolic blood pressure: A meta-analysis from the perspective of the number needed to treat
    Yu-Cheng Mao, Shiyao Ge, Su-Fen Qi, Qing‐Bao Tian · 2022 · Frontiers in Cardiovascular Medicine
  87. Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?
    Flávio Danni Fuchs, James J. DiNicolantonio · 2015 · Open Heart
  88. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: A nationwide study
    Chia-Jen Shih, Hsi Chu, Shuo‐Ming Ou, Yung‐Tai Chen · 2015 · International Journal of Cardiology
  89. Concepts in Diabetic Nephropathy: From Pathophysiology to Treatment
    Mustafa Kinaan, Hanford Yau, Suzanne Martinez, Pran M. Kar · 2017 · Journal of Renal and Hepatic Disorders
  90. How to Manage Hypertension in People With Diabetes
    Waleed Ali, George L. Bakris · 2020 · American Journal of Hypertension
  91. Recent therapeutic targets in diabetic nephropathy
    Marwa Mohsen, Ahmed Abdullah Elberry, Alaa Mohamed Rabea, Mohamed E. A. Abdelrahim, Raghda R. S. Hussein · 2021 · International Journal of Clinical Practice
  92. Diabetic Kidney Disease
    Radica Z. Alicic, Emily J. Johnson, Katherine R. Tuttle · 2018 · Elsevier eBooks
  93. The Goal of Blood Pressure Control for Prevention of Early Diabetic Microvascular Complications
    Mark E. Williams · 2011 · Current Diabetes Reports
  94. Olmesartan Improves Pulse Wave Velocity and Lowers Central Systolic Blood Pressure and Ambulatory Blood Pressure in Patients With Metabolic Syndrome
    Ulrike Raff, Stefanie Walker, Christian Ott, Markus Peter Schneider, Roland Erich Schmieder · 2014 · Journal of Clinical Hypertension
  95. Association Between Diabetic Microangiopathies and Glycemic Variability Assessed by Continuous Glucose Monitoring
    Satomi Sonoda, Yosuke Okada, Hiroko Mori, Fumi Uemura, Kei Sugai, Maiko Hajime, Kenichi Tanaka, Akira Kurozumi, Manabu Narisawa, Keiichi Torimoto et al. · 2018 · Journal of UOEH
  96. Inhibitors of the renin-angiotensin-aldosterone system
    Lionel Henry Opie, Marc Alan Pfeffer · 2013 · Elsevier eBooks
  97. Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
    Lucie Pothen, Jean‐Luc Balligand · 2021 · Antioxidants
  98. Renin–angiotensin–aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial
    Ana García‐Prieto, Úrsula Verdalles, A. Pérez de José, David Arroyo, Inés Aragoncillo, Diego Barbieri, Rosa Camacho, M. Goicoechea · 2024 · Hipertensión y Riesgo Vascular
  99. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in older adults with type 2 diabetes mellitus: a target trial emulation study
    Weihong Zeng, Tiansheng Wang, Til Stürmer, Na He, Peng Shen, Hongbo Lin, Xiaodong Guan, Yang Xu · 2025 · Cardiovascular Diabetology
  100. Cause-Specific Mortality According to Urine Albumin Creatinine Ratio in the General Population
    Tea Skaaby, Lise Lotte N. Husemoen, Tarunveer S. Ahluwalia, Peter R Rossing, Torben Jørgensen, Betina Heinsbæk Thuesen, Charlotta Holm Pisinger, Knud Rasmussen, Allan R Linneberg · 2014 · PLoS ONE